CoolMonth Returns with Exciting Offers on CoolSculpting® Elite by Allergan Aesthetics Allergan Aesthetics, an AbbVie company has announced the return of its third annual CoolMonth celebration, showcasing CoolSculpting® Elite. This…
CVS Health and Aetna Allocate $750,000 in Grants to Advance Health Outcomes Across Illinois CVS Health and Aetna Better Health® of Illinois, a CVS Health company, recently announced a combined…
HUB Organoids Merck Completes Acquisition of HUB Organoids Holding B.V., Expanding Next-Generation Biology Portfolio Merck, a global leader in science and technology, has finalized its acquisition of HUB Organoids Holding…
Trispecific WuXi Biologics a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a groundbreaking partnership with Candid Therapeutics, Inc. (“Candid”). Candid is a clinical-stage biotechnology firm aiming…
HIV Testing WHO Launches Guideline Development Group to Establish New HIV Prevention and Testing Standards for Lenacapavir The World Health Organization (WHO) has announced the formation of a new Guideline…
Biopharma Leaders M&A Didn’t Deliver as Expected in 2024: Biopharma Turns to JPMorgan Healthcare Conference for Optimism Biopharma Leaders the much-anticipated mergers and acquisitions (M&A) wave that the biopharma industry…
Astellas Pharma recently announced the approval Gastric Cancer of VYLOYTM (zolbetuximab) by China’s National Medical Products Administration (NMPA) for first-line treatment of locally advanced unresectable or metastatic human epidermal growth…
Revolution Medicines, a clinical-stage oncology company focused on developing targeted therapies for patients with RAS-addicted cancers, recently announced the successful closing of its upsized underwritten public offering. The offering comprised…
Heart Disease: The Importance of Regular Health Screenings Care Access, a leading health Heart Disease and research company, is bringing its Heart & Kidney Health Screening initiative to Pearland, Texas.…
Cytokinetics, Incorporated has announced the granting of equity awards as material inducements to new employees under Nasdaq Listing Rule 5635(c)(4). These grants, made on December 31, 2024, include stock options,…
Amid the growing global shortage of Pegasys® (peginterferon alfa-2a), PharmaEssentia (TWSE: 6446), a global biopharmaceutical company, is reaffirming its steadfast commitment to ensuring robust and reliable access to critical interferon…
The oncology pharmaceuticals market, valued at $196.4 billion in 2023, is expected to grow at a robust compound annual growth rate (CAGR) of 12.7%, reaching $401.4 billion by 2029. This…